Epigallocatechin-3-gallate Cross-Linked Small Intestinal Submucosa for Guided Bone Regeneration
Overview
Biotechnology
Authors
Affiliations
Collagen membranes are widely used in guided bone regeneration (GBR) because of their good biocompatibility and low immunogenicity. As a bioderived collagen membrane, small intestinal submucosa (SIS) has good regenerative potential for soft tissue repair, but it lacks sufficient mechanical properties for GBR application unless properly modifided. Epigallocatechin-3-gallate (EGCG) is a natural cross-linking agent featuring osteoinductive activity. In this study, we modified SIS by EGCG cross-linking, and such modified materials were characterized both and . The results showed that EGCG cross-linking significantly improved the mechanical properties and hydrophilicity of SIS while maintaing good cytocompatibility. Compared to SIS, EGCG-cross-linked SIS (E-SIS) enhanced the adhesion of fibroblasts and preosteoblasts and promoted the osteogenic differentiation of MC3T3-E1 cells cultured on the materials. In a rat cranial defect model, E-SIS material showed better occlusion effect than SIS material. Most importantly, E-SIS material accelerated bone regeneration more than SIS material and even a commercially available GBR membrane. Taken together, we conclude that E-SIS is a promising material as a GBR membrane.
Smart design in biopolymer-based hemostatic sponges: From hemostasis to multiple functions.
Zou C, Han C, Xing F, Jiang Y, Xiong M, Li-Ling J Bioact Mater. 2024; 45:459-478.
PMID: 39697242 PMC: 11653154. DOI: 10.1016/j.bioactmat.2024.11.034.
Lee D, Ko Y, Koo K, Seol Y, Lee Y, Lee J Biomater Res. 2024; 28:0113.
PMID: 39559494 PMC: 11570787. DOI: 10.34133/bmr.0113.
Macrophages in guided bone regeneration: potential roles and future directions.
Gou M, Wang H, Xie H, Song H Front Immunol. 2024; 15:1396759.
PMID: 38736888 PMC: 11082316. DOI: 10.3389/fimmu.2024.1396759.
Liang C, Liao L, Tian W Biomolecules. 2023; 13(4).
PMID: 37189420 PMC: 10136219. DOI: 10.3390/biom13040673.
Sapula P, Bialik-Was K, Malarz K Pharmaceutics. 2023; 15(1).
PMID: 36678882 PMC: 9866639. DOI: 10.3390/pharmaceutics15010253.